Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Craig H Moskowitz

Showing results (111-120 of 143) with videos related to

Pageof 15
Sort By:
Blood|May 23, 2013
Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphomaMatthew J Matasar, Myron S Czuczman, Maria Alma Rodriguez, et al.
Lancet (London, England)|March 23, 2015
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trialCraig H Moskowitz, Auayporn Nademanee, Tamas Masszi, et al.
Blood Advances|June 21, 2021
Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphomaParastoo B Dahi, Jasme Lee, Sean M Devlin, et al.
Blood|July 24, 2019
Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphomaDeborah M Stephens, Hongli Li, Heiko Schöder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2012
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphomaAnas Younes, Ajay K Gopal, Scott E Smith, et al.
Blood|July 3, 2019
CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphomaCraig S Sauter, Brigitte Senechal, Isabelle Rivière, et al.
Cancer|April 29, 2014
Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) projectKenneth R Carson, Scott D Newsome, Ellen J Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2010
Randomized clinical trial of telephone-administered cognitive-behavioral therapy to reduce post-traumatic stress disorder and distress symptoms after hematopoietic stem-cell transplantationKatherine N DuHamel, Catherine E Mosher, Gary Winkel, et al.
Blood Advances|January 25, 2024
Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOPKurt S Bantilan, Alexandra N Smith, Matthew J Maurer, et al.
Blood|February 17, 2019
Active surveillance for nodular lymphocyte-predominant Hodgkin lymphomaSven Borchmann, Erel Joffe, Craig H Moskowitz, et al.
Pageof 15

Showing results (111-120 of 143) with videos related to

Sort By:
Pageof 15
Blood|May 23, 2013
Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphomaMatthew J Matasar, Myron S Czuczman, Maria Alma Rodriguez, et al.
Lancet (London, England)|March 23, 2015
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trialCraig H Moskowitz, Auayporn Nademanee, Tamas Masszi, et al.
Blood Advances|June 21, 2021
Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphomaParastoo B Dahi, Jasme Lee, Sean M Devlin, et al.
Blood|July 24, 2019
Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphomaDeborah M Stephens, Hongli Li, Heiko Schöder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2012
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphomaAnas Younes, Ajay K Gopal, Scott E Smith, et al.
Blood|July 3, 2019
CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphomaCraig S Sauter, Brigitte Senechal, Isabelle Rivière, et al.
Cancer|April 29, 2014
Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) projectKenneth R Carson, Scott D Newsome, Ellen J Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2010
Randomized clinical trial of telephone-administered cognitive-behavioral therapy to reduce post-traumatic stress disorder and distress symptoms after hematopoietic stem-cell transplantationKatherine N DuHamel, Catherine E Mosher, Gary Winkel, et al.
Blood Advances|January 25, 2024
Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOPKurt S Bantilan, Alexandra N Smith, Matthew J Maurer, et al.
Blood|February 17, 2019
Active surveillance for nodular lymphocyte-predominant Hodgkin lymphomaSven Borchmann, Erel Joffe, Craig H Moskowitz, et al.
Pageof 15